Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology

Grants

Funding Acknowledgements

Supported by grants from the Medical Research Council (UK) (no. MC-A656-5QD30), Maudsley Charity (no. 666), the Brain and Behavior Research Foundation, and Wellcome Trust (no. 094849/Z/10/Z) to Dr. Howes, and from the National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London.Dr. Howes has received investigator-initiated research funding from or participated in advisory or speaker meetings organized by AstraZeneca, Autifony, Bristol-Myers Squibb, Eli Lilly, Heptares, Janssen, Lundbeck, Leyden-Delta, Otsuka, Servier, Sunovion, Rand, and Roche. Dr. Agid has served on advisory boards or as a consultant or speaker for Bristol-Myers Squibb, Eli Lilly, Janssen-Ortho (Johnson & Johnson), Lundbeck, Mylan, Novartis, Otsuka, Roche, Sepracor, Sumitomo Dainippon, and Sunovion, andhe has research contracts with Boehringer Ingelheim, Janssen-Ortho, Neurocrine Biosciences, Otsuka, Pfizer, and Sunovion. Dr. de Bartolomeis has received research support from Janssen, Lundbeck, and Otsuka and lecture fees from Chiesi, Lundbeck, Roche, Sunovion, and Takeda; he has served on advisory boards for Eli Lilly, Jansen, Lundbeck, Otsuka, Roche, and Takeda. Dr. Bressan has received research grants from FAPESP (Sao Paulo Research Foundation), CNPq (National Council for Technological and Scientific Development, Brazil), AstraZeneca, Eli Lilly, Janssen, Lundbeck, and Roche and has served on advisory boardsor as a speaker for Ache, AstraZeneca, Eli Lilly, Janssen, Lundbeck, and Roche. Dr. Buchanan has served on advisory boards for AbbVie, Amgen, Boehringer Ingelheim, EnVivo, Lundbeck, and Takeda, as a consultant for AbbVie, and on a data safety monitoring board for Pfizer. Dr. Carpenter has served as a consultant for Allergan, Genentech, HealthAnalytics, Pharmagenesis, and Teva. Dr. Castle has received grant support from Allergen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Hospira, Janssen-Cilag, Lundbeck, Pfizer, and Roche and travel support, speaking honoraria, or consultancy fees from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Hospira, Janssen-Cilag, Lundbeck, Organon, Pfizer, Sanofi-Aventis, Servier, Shire, and Wyeth. Dr. Citrome has engaged in collaborative research with or received consulting or speaking fees from Acadia, Alexza, Alkermes, Allergan, AstraZeneca, Avanir, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Forum, Genentech, Janssen, Jazz, Lundbeck, Merck, Medivation, Mylan, Neurocrine, Novartis, Noven, Otsuka, Pfizer, Reckitt Benckiser, Reviva, Shire, Sunovion, Takeda, Teva, Valeant, and Vanda. Dr. Daskalakis has received research and equipment in-kind support for an investigatorinitiated study through Brainsway and MagVenture; he has served on advisory boards for Sunovion, Hoffmann-La Roche, and Merck and has received speaker support from Eli Lilly. Dr. Davidson has received research support, travel support, speaking fees, or consulting fees from Eli Lilly, Forum, Johnson & Johnson, Lundbeck, Minerva, Roche, Servier, Takeda, and Teva, and he holds stocks in Minerva and CTR. Dr. Drake has received honoraria for advisory board participation or as a speaker for Janssen, Lundbeck, and Otsuka. Dr. Ebdrup has received lecture fees from Bristol Myers Squibb, Eli Lilly, and Otsuka and has served on advisory boards for Eli Lilly, Janssen-Cilag, and Takeda. Dr. Elkis has received research grants from FAPESP, Janssen, and Roche and honoraria for travel support, advisory board participation, or speaking from Ache, Daiichi-Sankyo, Cristalia, Janssen, and Roche. Dr. Fleischhacker has received research grants from Boehringer Ingelheim, Janssen-Cilag, Otsuka, and Lundbeck and speaking fees and advisory board honoraria from Amgen, AOP Orphan, Boehringer Ingelheim, Dainippon Sumitomo, Janssen, Lundbeck, Otsuka, Richter, Roche, Takeda, and Teva. Dr.Gadelhahas participatedon advisory boards for Janssen-Cilag and Daiichi-Sankyo. Dr. Gaughran has received support or honoraria for CME, advisorywork, and lectures from Bristol-Myers Squibb, Janssen, Lundbeck, Otsuka, Roche, and Sunovion; she has received research funding from an NHS Innovations/Janssen-Cilag award; and has a family member with professional links to Eli Lilly and GlaxoSmithKline, including share options. Dr. Glenthoj is the leader of a Lundbeck Foundation Center of Excellence (CINS, the Lundbeck Foundation Centre for Clinical Intervention andNeuropsychiatric Schizophrenia Research), which is partially financed by an independent grant from the Lundbeck Foundation. Dr. Honer has served on advisory boards or consulted for In Silico, Roche, Otsuka/Lundbeck, and Eli Lilly. Dr. Kennedy has received lecture honoraria from Novartis, PurduePharma, andShire. Dr. Kinonisan employee of Lundbeck LLC and a shareholder in Lundbeck and Eli Lilly. Dr. Lawrie has received research support from AbbVie, Janssen, Roche, and Sunovion, fees for advisory panel service from Forumand Janssen, and travel support from Otsuka. Dr. Lee has received travel support and honoraria from Janssen-Cilag and Roche. Dr. Leweke has received honoraria for lectures from AstraZeneca and is a shareholder in Curantis UG. Dr. Meltzer has received grant support from ACADIA, Allergan, Central Research Labs, Dainippon Sumitomo, Eli Lilly, Forum, Janssen, Lundbeck, Neurocrine, Reviva, Sunovion, and Takeda, andhe is a shareholder in ACADIA. Dr. Muller has received honoraria for lectures or advisory activities for Bayer, Eli Lilly, Lundbeck, Schwabe, and Servier; he was president or on the executive board of CINP, ECNP, WFSBP, and EPA and chairman of the WPA section on pharmacopsychiatry. Dr. Pantelis has participated on advisory boards for Janssen-Cilag, AstraZeneca, Lundbeck, and Servier and has received honoraria for talks presented at educational meetings organized by AstraZeneca, Eli Lilly, Janssen-Cilag, Lundbeck, Pfizer, and Shire. Dr. Reis Marques has served as a speaker for Lundbeck. Dr. Remington has received research support from Novartis and has served as a speaker or consultant for Neurocrine Biosciences, Novartis, and Synchroneuron. Dr. Siu has received funding and consulting fees from Sunovion, Pfizer, Hong Kong Health and Medical Research Grant, and the Chinese University of Hong Kong that support research and the use of clinical trial and genetic databases for analyses, publications, and data science activities. Dr. Suzuki has received manuscript or speaker's fees from Astellas, Dainippon Sumitomo, Eli Lilly, Elsevier Japan, Janssen, Meiji Seika, Novartis, Otsuka, and Wiley. Dr. Taylor has received research funding from Janssen, Lundbeck, and Sunovion and advisory board or speaking fees from Janssen, Lundbeck, Otsuka, Servier, and Sunovion. Dr. Thomas has received honoraria for talks presented at educationalmeetings organized by Janssen-Cilag. Dr. Umbricht is a full-time employee of Hofmann-La Roche and owns stock in Hofmann-La Roche and Novartis. Dr. Kane has served as a consultant for or received honoraria from Alkermes, Eli Lilly, EnVivo Pharmaceuticals (Forum), Forest (Allergan), Genentech, Intra-Cellular Therapies, Janssen, Johnson & Johnson, Lundbeck, Otsuka, Reviva, Roche, Sunovion, and Teva and has received grant support from Janssen and Otsuka; he is a shareholder in MedAvante, LB Pharmaceuticals, and Vanguard Research Group. Dr.Correll has received grant support from Bristol-Myers Squibb, Lundbeck, Otsuka, and Takeda; he has served as a consultant or adviser to or has received honoraria from AbbVie, Acadia, Actavis, Actelion, Alexza, Alkermes, Bristol-Myers Squibb, Cephalon, Eli Lilly, Forum, Genentech, Gerson Lehrman Group, Intra-Cellular Therapies, Janssen/Johnson& Johnson, Lundbeck, MedAvante, Medscape, Merck, Otsuka, Pfizer, ProPhase, Reviva, Roche, Sunovion, Supernus, Takeda, Teva, and Vanda; he has provided expert testimony for Bristol-Myers Squibb, Janssen, and Otsuka, and he has served on data safety monitoring boards for Eli Lilly, Janssen, Lundbeck, Otsuka, Pfizer, and Takeda. The other authors report no financial relationships with commercial interests.